<DOC>
	<DOCNO>NCT01645696</DOCNO>
	<brief_summary>The purpose study investigate accuracy performance new subcutaneous continuous glucose monitor ( BD-CGM , Becton Dickinson ) hyperglycemic ( high blood sugar ) hypoglycemic ( low blood sugar ) `` clamp '' condition meal excursion course 72 hour compare commercially available monitor .</brief_summary>
	<brief_title>Three-day , In-clinic Evaluation BD 2nd Generation Continuous Glucose Sensor Device Type 1 Diabetics</brief_title>
	<detailed_description>This single site , non-randomized study . The study consist Screening Visit ( Visit 1 ) subject consent inclusion exclusion criterion confirm . An interventional visit ( Visit 2 ) consist 72 hour in-clinic stay Follow-up Visit ( Visit 3 ) . Subjects eligible study admit clinic Study Visit 2 afternoon day first Clamp perform . An IV line blood sample establish . One blood sample obtain glucose determination second blood sample collect immunoassay development sensor insert . Two BD-Glucose Binding Protein-Continuous Glucose Monitor Sensors ( BD-GBP-CGM ) , without out layer , one commercial CGM sensor insert subcutaneous tissue abdomen shortly thereafter . Blood sample interval adjust 3 study day determine study event ( i.e . clamp period , meal excursion , nighttime ) . During hyper- /hypo-glycemic clamp period Day 1 Day 3 blood sample take frequently , every 5-10 minute . During breakfast meal Day 2 sample occur 10-15 minute interval 4 hour capture meal excursion . Sampling less frequent even meal night sleep hour .</detailed_description>
	<criteria>1 . Clinical diagnosis type 1 diabetes mellitus ≥1 year . For individual enrol least one criterion list must meet . 2 . Criteria document hyperglycemia ( least 1 must meet ) : 1 . Fasting glucose ≥ 7 mmol/L [ 126 mg/dL ] confirm 2 . Twohour OGTT ( oral glucose tolerance test ) glucose ≥ 11.1 mmol/L [ 200 mg/dL ] confirm 3 . HbA1c ≥6.5 % document confirmed 4 . Random glucose ≥ 11.1 mmol/L [ 200 mg/dL ] symptom 5 . No data diagnosis available participant convince history hyperglycemia consistent diabetes 3 . Criteria require insulin diagnosis ( 1 must meet ) : 1 . Participant required insulin diagnosis continually thereafter 2 . Participant start insulin diagnosis upon investigator review likely need insulin ( significant hyperglycemia respond oral agent ) require insulin eventually use continually 3 . Participant start insulin diagnosis continue hyperglycemic , positive islet cell antibody consistent latent autoimmune diabetes adult ( LADA ) require insulin eventually use continually 4 . Signed informed consent 5 . Age ≥18 ≤65 year old 6 . Body mass index 19 35 kg/m2 , inclusive 7 . HbA1c ≤ 10.0 % 1 . Uncontrolled arterial hypertension ( diastolic blood pressure &gt; 90 mm Hg and/or systolic blood pressure &gt; 160 mm Hg ) 2 . Impaired hepatic function measure alanine aminotransferase aspartate aminotransferase ≥ three time upper reference limit 3 . Impaired renal function measure creatinine &gt; 1.2 time upper limit normal 4 . Diabetic ketoacidosis past 6 month 5 . Severe hypoglycemia result seizure loss consciousness 6 month prior enrollment 6 . Conditions may increase risk hypoglycemia condition know microvascular ( diabetic ) complication assess individual basis exclusion base discretion principal investigator . 7 . Current use medication contain &gt; 4000 mg acetaminophen per day . 8 . Current use MAO ( monoamine oxidase ) inhibitor . 9 . Known allergy egg 10 . Pregnancy , breastfeed intention become pregnant 11 . Current recent alcohol drug abuse subject history . 12 . Blood donation 473 ml within last 56 day 13 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 14 . Any skin condition prevents sensor placement abdomen ( e.g. , bad sunburn , preexist dermatitis , intertrigo , psoriasis , extensive scarring , cellulitis ) 15 . Known allergy medical adhesive , e.g . Tegaderm 16 . Hematocrit &lt; 38 % ( male ) &lt; 36 % ( female ) 17 . Potassium &lt; 3.4 mmol/L 18 . Active enrollment another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Continuous glucose monitoring</keyword>
	<keyword>Blood glucose</keyword>
	<keyword>Blood glucose sensor</keyword>
	<keyword>Glucose Binding Protein ( GBP )</keyword>
</DOC>